Psychedelics in the Pipeline: What the New Executive Order Means for Mental Health Care

On April 18, 2026, President Donald J. Trump signed an executive order directing federal agencies to accelerate access to psychedelic therapies for patients with serious mental illness. The order instructs the FDA to issue Commissioner's National Priority Vouchers to psychedelic medications that have received Breakthrough Therapy designation, establishes a Right to Try pathway for eligible patients to access investigational psychedelics, including ibogaine compounds, and allocates $50 million through the ARPA-H program to match state investments in psychedelic research. It also directs the DEA to initiate rescheduling reviews upon completion of phase 3 clinical trials and calls on the Department of Veterans Affairs and the private sector to expand clinical trial participation.¹

To help clinicians make sense of the science, the regulatory landscape, and the practical implications for everyday practice, we spoke with Gus Alva, MD, a Distinguished Fellow of the American Psychiatric Association and an active clinical investigator in the psychedelic research space.

Making Sense of the Executive Order on Psychedelic Therapies, with Gus Alva, MD

Q: What is the most compelling aspect of the scientific rationale behind psychedelic therapies, particularly in terms of mechanism and potential durability of response?

A: Psychedelics primarily act through 5-HT2A receptor activation, but what makes them genuinely novel is that they do not simply modulate receptor activity in a conventional pharmacological sense. What they appear to do is open a window of heightened neuroplasticity — a transient state in which the brain becomes more capable of forming new associations and updating its internal models. That has meaningful clinical implications.

There is evidence, for instance, that rapid increases in prefrontal cortical dendritic spine density may produce both an acute therapeutic effect and a more sustained one. Separately, psychedelics appear to disintegrate the default mode network, which is significant because rigid default mode activity underlies the ruminative, self-referential processing that characterizes severe depression. There is also what some researchers describe as the REBUS model — "Relaxed Beliefs Under Psychedelics" — which posits that psychedelics down-weight prior belief systems and allow for cognitive updating that would otherwise be resistant to standard interventions.

What distinguishes this mechanistic profile from conventional pharmacotherapy is the potential to modify the disease state itself, not merely suppress symptomatology. That is the hypothesis, and it is why this field warrants serious scientific attention, though considerable work remains to be done.

Q: How do you interpret the current evidence base surrounding psychedelic therapies in psychiatric disorders?

A: This is another very important area because right the signal-to-noise ratio is a problem, and the signal is clearly real. On the psilocybin side, we have well-designed registration clinical trials — including work published in JAMA and the New England Journal of Medicine — demonstrating large effect sizes at three to six weeks in treatment-resistant depression and major depressive disorder, compared against active comparators. For MDMA, two phase 3 trials in PTSD showed positive results with durable reductions on the CAPS-5 scale. Ibogaine has been studied in special operations veterans at Stanford, with early data suggesting benefit in PTSD and traumatic brain injury, and there is also a body of literature on its use in opioid dependence, though its cardiotoxic profile warrants careful attention.

That said, there are real methodological concerns that the field has not yet resolved. Blinding integrity is a fundamental challenge — participants can generally identify whether they received an active agent, which complicates any placebo-controlled interpretation. There is also the question of how to cleanly separate the pharmacological effect of the psychedelic from the hours of specialized psychotherapy that are embedded in the treatment protocol. Additionally, there are legitimate concerns that adverse event reporting in some trials may have been incomplete. The FDA's rejection of the initial MDMA-assisted therapy application reflected some of these concerns, and the field needs to take them seriously rather than dismiss them. The evidence is promising, but it is not yet definitive.

Q: As policy efforts aim to accelerate development and access—including investigational pathways—what should general clinicians be mindful of when patients begin asking about these therapies?

A: The first and most important thing a generalist can do is take the question seriously. A patient who asks about psychedelic therapy is not asking an eccentric question — they are communicating, often implicitly, that their current treatment is not meeting their needs. That message deserves to be heard and acknowledged. If a clinician dismisses the question outright, they risk pushing that patient toward unsupervised, unregulated use — retreat centers, unlicensed providers — and that is a genuinely dangerous outcome.

Clinicians should understand the basic regulatory landscape. Ketamine is available off-label for treatment-resistant depression and is widely used. Esketamine (Spravato®; Johnson & Johnson) has FDA approval for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy.² Everything else — psilocybin, MDMA, ibogaine, LSD, DMT — remains investigational. The Right to Try pathway established by this executive order applies narrowly and requires specific criteria. Oregon and Colorado have created state-level frameworks that occupy something of a federal gray zone, but those are not the same as FDA approval.

From a screening standpoint, primary care physicians (PCPs) should be aware of features that significantly elevate risk in the context of psychedelic exposure: a personal or family history of bipolar disorder, psychosis, or cardiac conditions should trigger careful assessment before any encouragement of access to these agents. Patients should also be cautioned against unregulated settings, which carry real risks of psychological harm and exploitation. PCPs do not need to become psychedelic therapy experts. But they should be able to have a non-judgmental conversation, identify patients with high-risk clinical features, and refer appropriately — including, where relevant, to investigators who are conducting clinical research in the community. Most patients seeking out these therapies have already failed or derived only partial benefit from available modalities. They are individuals with higher acuity, potentially higher risk tolerance, and often a high index of hope. That combination deserves thoughtful, informed engagement.

Q: These therapies often require structured administration and integration with psychotherapy—how far is the field from having the infrastructure and training to deliver this safely at scale?

A: Psychiatry is an adaptable field, but the honest answer is that we are nowhere near having the infrastructure or the trained workforce required for safe delivery at scale. These are not standard outpatient encounters. Dosing sessions typically require six to eight hours of direct facilitation, with both psychological support and medical backup, appropriate physical space, and structured integration sessions before and after the dosing experience. The overall therapeutic model demands a level of competency that most clinicians have not been trained to provide.

In my own experience as an investigator, therapists working in this space require upward of 100 hours of specialized training before they are considered qualified to facilitate sessions. We simply do not have a therapist pool in the US that could meet that demand at present. Compounding that, clinicians need to be equipped to manage adverse events in real time — difficult psychological experiences, acute psychotic symptoms, post-session suicidality, and cardiac events, particularly with agents like ibogaine.

There are also documented concerns about therapist boundary violations that emerged during the MDMA trials, which underscore why this infrastructure gap is not a minor logistical issue — it is a patient safety issue. A robust training pipeline is an absolute prerequisite, and that pipeline does not currently exist.

References:

1. The White House. Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness. April 18, 2026. Accessed April 20, 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/
2. Johnson & Johnson. SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression [news release]. January 21, 2025. Accessed January 21, 2025. https://www.investor.jnj.com/news/news-details/2025/SPRAVATO-esketamine-approved-in-the-U.S.-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression/default.aspx